- OPTIMIZE-1 is assessing the safety and efficacy of mitazalimab in combination with mFOLFIRINOX in 1st line metastatic pancreatic cancer
- Interim efficacy results demonstrated a 52% Objective Response Rate
- Interim Progression Free Survival and survival expected mid-2023
- Top-line data expected in the beginning of Q1 2024
Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the completion of patient enrolment in the ongoing OPTIMIZE-1 Phase 2 trial of the company's lead asset mitazalimab in 1st line metastatic pancreatic cancer. Thanks to this acceleration in patient enrolment, Alligator confirms it expects to report top-line data in the beginning of Q1 2024.
The open-label, multi-center study is assessing the safety and efficacy of mitazalimab (CD40 mAb) in combination with chemotherapy, mFOLFIRINOX, in previously untreated patients with metastatic pancreatic ductal adenocarcinoma.
"The completion of enrolment in OPTIMIZE-1 marks another important milestone in our clinical development of mitazalimab, which has been demonstrating outstanding potential in pancreatic cancer when combined with chemotherapy," said Søren Bregenholt, CEO of Alligator Bioscience. "Patient enrolment has been completed earlier than initially anticipated thanks to the diligent work of the Alligator organisation, thus significantly de-risking the program. The strong interim data released earlier this year showing an objective response rate (ORR) in excess of 50%, coupled with the high unmet medical need of patients with metastatic pancreatic cancer, has spurred significant interest in mitazalimab in the medical community and with potential partners. We are confident in the potential of mitazalimab as first-line treatment and looking forward to key survival data due later this year, and ultimately to the top-line readout expected at the beginning of next year."
In January 2023, Alligator announced strong interim results from OPTIMIZE-1, in which mitazalimab combined with mFOLFIRINOX demonstrated an ORR of 52% in 23 evaluable patients, as per the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). In comparison, a similar patient population treated only with FOLFIRINOX reported an ORR of around 32%[1]. Mitazalimab in combination with mFOLFIRINOX also reported an interim disease control rate, the proportion of patients with objective response or stabilization of disease, of over 90%.
Alligator is planning to initiate discussions with regulators in the US and Europe on the best possible development and approval pathway for mitazalimab in pancreatic cancer later this year. Interim data from OPTIMIZE-1 on Progression Free Survival[2] and survival are due in mid-2023 and top-line data are expected in Q1 2024.
[1] Conroy et al, N Engl J Med 2011; 364:1817-1825; DOI: 10.1056/NEJMoa1011923
[2] Reflective of how long it take patients to have their disease progress